FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy
RegulatoryGazyva/GazyvaroPositive
AI Analysis
Summary
Roche's Gazyva/Gazyvaro (obinutuzumab) received FDA Priority Review for primary membranous nephropathy based on positive Phase III MAJESTY trial data showing superiority over tacrolimus, with an expected FDA decision by November 2026.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
FDA granted Priority Review to sBLA; positive Phase III MAJESTY results showed superiority over tacrolimus
Importance:8/10
Sentiment:
0.85
FDAPriority ReviewBreakthrough Therapy DesignationPhase 3NephrologysBLAImmunology
Related Companies
Read the original article
Published by GlobeNewswire Pharma on July 15, 2026 5:00 AM